Wegovy

How to order Wegovy

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Wegovy on Prescriptsy

Wegovy is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Wegovy is a prescription-only medicine containing semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist administered as a once-weekly subcutaneous injection for chronic weight management.

It is indicated for adults with a body mass index (BMI) of 30 kg/m2 or above (obesity) or 27 kg/m2 or above (overweight) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea.

Wegovy is used alongside a reduced-calorie diet and increased physical activity.

It is manufactured by Novo Nordisk and is classified as a prescription-only medicine (POM) in the United Kingdom.

Obesity is a chronic, relapsing disease that affects approximately 26% of adults in England, with a further 38% classified as overweight.

It is a leading modifiable risk factor for type 2 diabetes, cardiovascular disease, certain cancers, musculoskeletal disorders, and reduced life expectancy.

The pathophysiology of obesity involves a complex interplay of genetic, neurohormonal, environmental, and behavioural factors that regulate energy balance.

Weight regain after dietary weight loss is driven by persistent physiological adaptations including reduced energy expenditure, altered gut hormone profiles, and increased appetite signalling.

These factors mean that sustained weight management typically requires ongoing pharmacological or surgical intervention in addition to lifestyle modification.

This page provides a comprehensive clinical guide to Wegovy, covering its mechanism of action, dosage, side effects, safety warnings, and how to obtain a prescription in the United Kingdom.

Important safety information about Wegovy

Before reading further, note these essential safety points.

• Wegovy must not be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
• Stop Wegovy and seek urgent medical attention if you develop severe, persistent abdominal pain (possible pancreatitis).
• Wegovy must not be used during pregnancy. Use effective contraception during treatment and for at least 2 months after stopping.
• If you experience new or worsening mood changes, depression, or thoughts of self-harm, contact your prescriber immediately.

Understanding obesity as a chronic disease

Obesity is recognised by the World Health Organization, the Royal College of Physicians, and NICE as a chronic disease rather than simply a lifestyle choice.

Body weight is regulated by a homeostatic system centred in the hypothalamus, which integrates signals from peripheral hormones (leptin from adipose tissue, ghrelin from the stomach, GLP-1 and PYY from the intestine, insulin from the pancreas) to control appetite, satiety, and energy expenditure.

In people with obesity, this regulatory system is shifted toward a higher defended body weight, meaning that the body actively resists weight loss by increasing hunger signals and reducing metabolic rate when caloric intake is restricted.

This explains why lifestyle modification alone achieves modest long-term weight loss (typically 3% to 5% of body weight) in most people.

The body's physiological response to caloric restriction makes sustained weight loss through diet and exercise alone extremely difficult for many individuals.

Pharmacotherapy targets these physiological mechanisms, helping to reduce appetite, increase satiety, or alter nutrient absorption.

Semaglutide 2.4 mg (Wegovy) represents a significant advance in pharmacological weight management, achieving average weight loss comparable to some bariatric surgical procedures.

How Wegovy works

Semaglutide is a long-acting analogue of human glucagon-like peptide-1 (GLP-1), a gut hormone released by L-cells in the ileum and colon in response to food intake.

Semaglutide shares 94% structural homology with native GLP-1, but modifications to the molecule (an amino acid substitution at position 8, a C-18 fatty diacid chain linked via a spacer to lysine at position 26) increase its resistance to degradation by dipeptidyl peptidase-4 (DPP-4) and enhance albumin binding.

These modifications extend the half-life from approximately 2 minutes (native GLP-1) to approximately 1 week, enabling once-weekly dosing.

Semaglutide acts on GLP-1 receptors at multiple sites.

In the hypothalamus, it activates neurons in the arcuate nucleus (particularly POMC/CART neurons) and inhibits NPY/AgRP neurons, reducing hunger and increasing satiety.

This central appetite suppression is considered the primary mechanism for weight loss.

In the brainstem, semaglutide acts on the area postrema and nucleus tractus solitarius, areas involved in nausea and satiety signalling, which explains both the appetite-reducing effect and the common gastrointestinal side effects.

In the gastrointestinal tract, semaglutide slows gastric emptying, which prolongs postprandial satiety and reduces the rate of nutrient absorption.

In the pancreas, semaglutide stimulates glucose-dependent insulin secretion and suppresses glucagon release, contributing to glycaemic control in patients with type 2 diabetes.

Clinical evidence for Wegovy: the STEP programme

Wegovy was approved based on the Semaglutide Treatment Effect in People with obesity (STEP) clinical trial programme, one of the largest and most comprehensive weight management trial programmes conducted to date.

STEP 1 enrolled 1,961 adults with BMI 30 or above (or 27 or above with a weight-related comorbidity) without type 2 diabetes.

At 68 weeks, participants taking semaglutide 2.4 mg lost an average of 14.9% of their initial body weight, compared with 2.4% in the placebo group.

Approximately one-third of participants achieved weight loss of 20% or more. These results are unprecedented for a non-surgical weight management intervention.

STEP 2 enrolled 1,210 adults with type 2 diabetes and BMI 27 or above.

At 68 weeks, semaglutide 2.4 mg produced average weight loss of 9.6%, compared with 3.4% with placebo.

The lower weight loss in this population is consistent with the observation that weight loss with GLP-1 agonists is typically more modest in people with type 2 diabetes.

STEP 3 combined semaglutide 2.4 mg with intensive behavioural therapy (30 counselling sessions over 68 weeks) and an 8-week low-calorie diet at the start.

Average weight loss was 16% at 68 weeks, suggesting that combining pharmacotherapy with intensive behavioural support can further enhance outcomes.

STEP 4 investigated the effect of continuing versus stopping semaglutide after 20 weeks of treatment.

Patients who continued semaglutide lost an additional 7.9% of body weight over the subsequent 48 weeks, while those switched to placebo regained 6.9%, demonstrating the importance of ongoing treatment for weight maintenance.

The SELECT cardiovascular outcomes trial demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.

This landmark result established semaglutide as the first obesity pharmacotherapy to demonstrate a cardiovascular benefit.

NICE guidance and NHS access

NICE technology appraisal TA875 recommends semaglutide for weight management in adults with a BMI of 35 or above (or 30 or above in certain high-risk groups) who have at least one weight-related comorbidity, as part of a specialist weight management service.

NICE recommends that treatment is continued only if patients achieve at least 5% weight loss after 6 months at the maintenance dose.

Local NHS commissioning arrangements determine the specific pathway for accessing Wegovy, and availability may vary by region.

Dosage and administration

Wegovy is administered as a subcutaneous injection once weekly using a pre-filled pen.

The dose escalation schedule over 16 weeks helps to reduce gastrointestinal side effects: 0.25 mg weekly for month 1, 0.5 mg weekly for month 2, 1 mg weekly for month 3, 1.7 mg weekly for month 4, then the maintenance dose of 2.4 mg weekly from month 5 onwards.

Inject into the abdomen, thigh, or upper arm, rotating the site each week. The injection can be given at any time of day, with or without food.

If you miss a dose and the next scheduled dose is more than 2 days away, take the missed dose as soon as possible.

If the next dose is less than 2 days away, skip the missed dose.

If you have missed doses for more than 2 weeks, contact your prescriber about restarting the dose escalation.

Store Wegovy in the refrigerator before first use and dispose of used pens in a sharps container.

Side effects of Wegovy

Gastrointestinal effects

Nausea (44%), diarrhoea (30%), constipation (24%), vomiting (24%), and abdominal pain (20%) are the most commonly reported side effects.

These are related to the mechanism of action (slowed gastric emptying, central appetite suppression) and are most common during the dose escalation phase.

Most gastrointestinal symptoms are mild to moderate, tend to diminish over time, and can be managed with dietary modifications (smaller, more frequent meals, avoiding fatty or heavy foods).

Gastrointestinal side effects led to discontinuation in approximately 7% of clinical trial participants.

Other common side effects

Headache, fatigue, dizziness, dyspepsia, flatulence, and injection site reactions are also commonly reported. A small increase in resting heart rate (1 to 4 beats per minute) has been observed consistently across semaglutide trials.

Serious but less common side effects

Cholelithiasis (gallstones) occurs at a higher rate with semaglutide than placebo, likely related to rapid weight loss. Pancreatitis has been reported with GLP-1 agonists as a class.

Acute kidney injury has been reported, predominantly in the context of severe dehydration from gastrointestinal side effects.

Diabetic retinopathy complications have been reported in patients with pre-existing retinopathy and rapid glycaemic improvement. Anaphylaxis and angioedema are very rare.

Report suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Warnings and precautions

Thyroid C-cell tumours

Semaglutide caused dose-dependent thyroid C-cell tumours in rodent studies. Whether this risk translates to humans is unknown.

As a precaution, Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2).

Report any neck mass, dysphagia, dysphonia, or persistent hoarseness to your prescriber.

Pancreatitis

Acute pancreatitis has been reported with GLP-1 receptor agonists. Do not start Wegovy in patients with a history of pancreatitis.

If severe, persistent abdominal pain develops during treatment, stop Wegovy and seek urgent medical attention. If pancreatitis is confirmed, do not restart Wegovy.

Mental health

The MHRA has reviewed reports of suicidal thoughts and self-harm in patients taking GLP-1 receptor agonists.

While a causal relationship has not been confirmed, patients and prescribers should be vigilant. Seek medical attention for new or worsening depression, anxiety, or suicidal thoughts.

Pregnancy and contraception

Wegovy must not be used during pregnancy. Women of childbearing potential should use effective contraception.

Discontinue Wegovy at least 2 months before a planned pregnancy due to the long half-life of semaglutide.

Note that weight loss and semaglutide-related changes in gastrointestinal transit may reduce the efficacy of oral contraceptives; consider non-oral contraceptive methods.

How to get Wegovy in the UK

Wegovy is available on NHS prescription through specialist weight management services, subject to NICE criteria and local commissioning arrangements. It may also be prescribed privately.

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Your GP can refer you to a specialist weight management service if you meet the criteria, or you can discuss Wegovy with an authorised online prescriber registered with the GPhC.

Sources

• Wegovy, Summary of Product Characteristics (EMC)
• Semaglutide, British National Formulary (BNF)
• Semaglutide for managing overweight and obesity, NICE TA875
• Obesity, NHS
• Semaglutide 2.4 mg for weight management (STEP 1), New England Journal of Medicine
• MHRA Yellow Card Scheme